IGKV2-40: A Potential Drug Target and Biomarker (G28916)

Target Name: IGKV2-40

NCBI ID: G28916

Other Name(s): IGKV240 | O11 | O11a | immunoglobulin kappa variable 2-40 | Immunoglobulin kappa variable 2-40

IGKV2-40: A Potential Drug Target and Biomarker

The IGKV2-40 gene, located on chromosome 1p36.1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. IGKV2-40 is a non-coding RNA molecule that has been shown to play a role in regulating various cellular processes, including cell growth, differentiation, and survival. In this article, we will explore the potential implications of IGKV2-40 as a drug target and biomarker.

Potential Drug Target

The IGKV2-40 gene has been shown to be involved in several cellular processes that are crucial for human health and disease. One of the most significant functions of IGKV2-40 is its role in cell growth and differentiation. IGKV2-40 has been shown to play a negative role in the growth and proliferation of cancer cells, which makes it an attractive target for cancer therapies.

IGKV2-40 has also been shown to be involved in the regulation of cell survival and apoptosis, which are critical processes that are involved in the aging process and the development of neurodegenerative diseases. Additionally, IGKV2-40 has been shown to play a role in the regulation of immune cell function, which is crucial for the immune system's response to infection and disease.

Potential Biomarker

IGKV2-40 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. IGKV2-40 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that IGKV2-40 may be a useful biomarker for these diseases.

IGKV2-40 has also been shown to be a potential biomarker for identifying individuals at risk for developing cancer. Several studies have shown that IGKV2-40 levels are significantly lower in individuals with a family history of cancer compared to individuals without a family history of cancer. Additionally, IGKV2-40 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancers.

Conclusion

In conclusion, IGKV2-40 is a non-coding RNA molecule that has been shown to play a role in regulating various cellular processes, including cell growth, differentiation, and survival. The potential drug target and biomarker properties of IGKV2-40 make it an attractive target for further research and development. Further studies are needed to fully understand the role of IGKV2-40 in human health and disease.

Protein Name: Immunoglobulin Kappa Variable 2-40

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets